Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues.
Eckman
M H
MH
Division of General Medicine, New England Medical Center, Boston, MA 02111, USA.
Levine
H J
HJ
Salem
D N
DN
Pauker
S G
SG
D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D003663:Decision Trees; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006331:Heart Diseases / Q000150:complications; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008946:Mitral Valve Stenosis / Q000150:complications; D019057:Quality-Adjusted Life Years; D013923:Thromboembolism / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin